Tags

Type your tag names separated by a space and hit enter

Effect of olmesartan medoxomil on cystatin C level, left ventricular hypertrophy and diastolic function.
Blood Press. 2009; 18(4):187-91.BP

Abstract

Serum cystatin C concentration is an alternative measure of kidney function that is less affected by age, sex or muscle mass, and is a more sensitive indicator of early renal dysfunction than creatinine-based estimations of glomerular filtration rate. Cardiovascular sequela increases progressively with the increase in left ventricular mass. Our goal was to evaluate the effect of olmesartan medoxomil on cystatin C levels and left ventricular hypertrophy (LVH) in patients with hypertension. Forty-four newly diagnosed hypertensive patients (27 women and 17 men) were recruited in the study. Olmesartan medoxomil (20mg/day) was started and the patients were followed up for 6 months. Baseline echocardiographic findings (i.e. left ventricular mass index), serum creatinine, urine albumin/creatinine ratio (ACR) and serum cystatin C levels were compared with the levels of these variables measured at the end of 6-month follow-up period. After 6 months of treatment with olmesartan medoxomil, there was a significant reduction in systolic and diastolic blood pressure (p<0.001) and in urine ACR (p=0.04). Mean serum cystatin C levels decreased from 1.61+/-0.24 mg/l to 1.31+/-0.29 mg/l (p<0.001). Olmesartan medoxomil treatment also reduced left ventricular mass index (p<0.001) and LVH (p<0.001). Our findings indicate that olmesartan medoxomil decreases serum cystatin C levels, urine ACR and reduces LVH in patients with hypertension. To our knowledge, this study is the first to show that olmesartan medoxomil decreases serum cystatin C levels, indicating that in patients with essential hypertension it may counteract end organ damage.

Authors+Show Affiliations

Medicine Faculty Department of Cardiology, Duzce University, Duzce, Turkey.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

19521888

Citation

Albayrak, Sinan, et al. "Effect of Olmesartan Medoxomil On Cystatin C Level, Left Ventricular Hypertrophy and Diastolic Function." Blood Pressure, vol. 18, no. 4, 2009, pp. 187-91.
Albayrak S, Ordu S, Ozhan H, et al. Effect of olmesartan medoxomil on cystatin C level, left ventricular hypertrophy and diastolic function. Blood Press. 2009;18(4):187-91.
Albayrak, S., Ordu, S., Ozhan, H., Yazici, M., Aydin, M., Alemdar, R., & Kaya, A. (2009). Effect of olmesartan medoxomil on cystatin C level, left ventricular hypertrophy and diastolic function. Blood Pressure, 18(4), 187-91. https://doi.org/10.1080/08037050903047236
Albayrak S, et al. Effect of Olmesartan Medoxomil On Cystatin C Level, Left Ventricular Hypertrophy and Diastolic Function. Blood Press. 2009;18(4):187-91. PubMed PMID: 19521888.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of olmesartan medoxomil on cystatin C level, left ventricular hypertrophy and diastolic function. AU - Albayrak,Sinan, AU - Ordu,Serkan, AU - Ozhan,Hakan, AU - Yazici,Mehmet, AU - Aydin,Mesut, AU - Alemdar,Recai, AU - Kaya,Ahmet, PY - 2009/6/13/entrez PY - 2009/6/13/pubmed PY - 2010/12/28/medline SP - 187 EP - 91 JF - Blood pressure JO - Blood Press VL - 18 IS - 4 N2 - Serum cystatin C concentration is an alternative measure of kidney function that is less affected by age, sex or muscle mass, and is a more sensitive indicator of early renal dysfunction than creatinine-based estimations of glomerular filtration rate. Cardiovascular sequela increases progressively with the increase in left ventricular mass. Our goal was to evaluate the effect of olmesartan medoxomil on cystatin C levels and left ventricular hypertrophy (LVH) in patients with hypertension. Forty-four newly diagnosed hypertensive patients (27 women and 17 men) were recruited in the study. Olmesartan medoxomil (20mg/day) was started and the patients were followed up for 6 months. Baseline echocardiographic findings (i.e. left ventricular mass index), serum creatinine, urine albumin/creatinine ratio (ACR) and serum cystatin C levels were compared with the levels of these variables measured at the end of 6-month follow-up period. After 6 months of treatment with olmesartan medoxomil, there was a significant reduction in systolic and diastolic blood pressure (p<0.001) and in urine ACR (p=0.04). Mean serum cystatin C levels decreased from 1.61+/-0.24 mg/l to 1.31+/-0.29 mg/l (p<0.001). Olmesartan medoxomil treatment also reduced left ventricular mass index (p<0.001) and LVH (p<0.001). Our findings indicate that olmesartan medoxomil decreases serum cystatin C levels, urine ACR and reduces LVH in patients with hypertension. To our knowledge, this study is the first to show that olmesartan medoxomil decreases serum cystatin C levels, indicating that in patients with essential hypertension it may counteract end organ damage. SN - 1651-1999 UR - https://www.unboundmedicine.com/medline/citation/19521888/Effect_of_olmesartan_medoxomil_on_cystatin_C_level_left_ventricular_hypertrophy_and_diastolic_function_ L2 - https://www.tandfonline.com/doi/full/10.1080/08037050903047236 DB - PRIME DP - Unbound Medicine ER -